Revive Therapeutics Ltd. Announces Progress on Bucillamine Countermeasure Study

Revive Therapeutics Ltd. (RVVTF), a Canadian health‑care company listed on the Canadian National Stock Exchange, released an update on its ongoing Phase II‑A clinical studies for bucillamine (REV‑002) and disclosed preliminary results from a study involving the Defense Research and Development Canada (DRDC) nerve‑agent countermeasure program.

Key Points

  • Clinical Development of REV‑002

  • Revive has completed Phase II‑A trials for its cannabinoid‑based bucillamine, aimed at treating acute gout flares.

  • The company’s website, www.revivethera.com , provides additional details on the product’s development status.

  • DRDC Study Collaboration

  • The company is collaborating with DRDC to evaluate bucillamine as a potential countermeasure against nerve agents.

  • Initial data from the study were presented on 21 November 2025 and highlight the compound’s pharmacological profile in this context.

  • Market Context

  • As of 19 November 2025, Revive’s share price closed at CAD 0.01.

  • The company’s 52‑week range is CAD 0.005 (low) to CAD 0.035 (high).

  • Its market capitalization stands at approximately CAD 4.19 million.

Sources of Information

  • StockWatch (21 Nov 2025) reported the company’s discussion of the DRDC study.
  • FeedBurner (21 Nov 2025) provided a detailed update on the nerve‑agent countermeasure research.
  • GlobeNewswire (21 Nov 2025) published a similar briefing on the study.

These releases collectively underscore Revive Therapeutics’ dual focus on therapeutic development for gout and defense‑related applications of its cannabinoid platform.